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Background: Information regarding recruitment of infants to research studies following the diagnosis of cystic ﬁbrosis (CF) via newborn screening
(NBS) is not currently available. This study aimed to assess parental attitudes and the feasibility of recruiting and retaining both NBS infants with
CF and healthy control infants to a longitudinal, observational study.
Methods: All infants underwent pulmonary function tests (PFTs) at ~3 and ~12 months of age. Infants with CF had additional combined chest high
resolution computed tomography (HRCT), bronchoscopy and broncho-alveolar lavage (BAL) at ~12 months of age. Parental attitude questionnaires
(PAQs) were administered to all parents following the ~3 month PFTs and to parents of infants with CF after completion of all tests at ~12 months.
Results: 86% (92/107) of families whose infant had CF consented to participate, of whom 92%had PFTs at ~3 months of age with 99% of these having
PFTs at ~12 months of age. Recruitment of healthy controls was feasible but more challenging; 29% of those contacted agreed to participate; 73% of
these had PFTs at ~3 months of age; of whom 83% had repeated PFTs at ~12 months of age. Completed PAQs were received from 71% of parents,
(both of CF and healthy infants) at ~3 months and from 58% parents of infants with CF at ~12 months. Responses from the PAQs were generally
positive, 95% of parents indicated they would recommend participation in such studies to other families. Discrepancies between responses at 3 and
12 months suggested that parental understanding of what the research entailed developed during the course of the study.
Conclusions: The high recruitment and retention rates for newly diagnosed CF NBS infants to this observational study are encouraging. These
ﬁndings will help inform future study design both in the ﬁeld of CF and other conditions diagnosed by NBS.
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NBS for infants in the United Kingdom (UK) (initially for
phenylketonuria) commenced in 1969 and has since expanded to
include several clinical conditions. NBS for CF has been
universally available in the UK since 2007. The challenges of
imparting NBS results of carrier status for CF and sickle cellby Elsevier B.V. All rights reserved.
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that the initial communication of the diagnosis of CF can lead to
parental feelings of fear and despair [3]. Consequently, recruiting
NBS infants to research studies at this time could be problematic
and should be handled sensitively.
It is essential that caregiver views on participating in all
research, particularly research that places the child in a vulnerable
position are appreciated. Data regarding parental attitudes to their
child's involvement in research are, however, only available from
parents of preterm infants [4–9] and older children [10–13].
There are currently no published studies regarding recruitment of
infants to studies following the diagnosis of a chronic illness via
NBS. The feasibility of recruiting infants within the first few
weeks following a NBS diagnosis of CF or any other condition to
studies that require sedation or general anaesthesia to assess
outcomes from pulmonary function tests, bronchial lavage or
chest CT scans has yet to be ascertained. Equally, the extent to
which previous findings regarding parental attitudes [4–13] can
be extrapolated when studying infants diagnosed with CF by
NBS remains unknown.
Involvement of healthy infants in research remains a conten-
tious issue particularly if sedation is required as is generally
necessary for PFTs [14]. However, the necessity of obtaining
normative data in order to distinguish the effects of growth and
development from those of disease in a meaningful fashion has
been clearly established [14–17]. In addition, it has been
recognised that the use of historical controls or reference data
derived from equipment other than that used for any specific
study can severely distort interpretation of infant PFT results
[14,16].
The primary aims of this study were to assess the feasibility
of recruiting and retaining infants diagnosed with CF by NBS
to a longitudinal observational study that required sedation for
serial PFTs and general anaesthesia (GA) for Bronchoscopy
and CT scans at a year of age, and to investigate parental
attitudes to participating in such a study. A secondary aim was
to assess the feasibility of recruiting and retaining healthy
control infants into a longitudinal study of lung function.
2. Methods
2.1. Study design
This observational study was designed to assess the evolution
of lung function and structure in NBS infants with CF and to
address recruitment and retention issues and parental attitudes.
Infants with CF and healthy controls underwent PFTs (using
multiple breath washout [18], whole body plethysmography [19]
and the raised volume technique [20]) under oral/rectal chloral
hydrate sedation (60–100 mg/kg) at ~3 and ~12 months of age.
Additionally, infants with CF had combined high resolution
computer tomography chest scans (HRCT), bronchoscopy and
broncho-alveolar lavage (BAL) under GA at ~12 months of age.
Parental attitude questionnaires (PAQs) were devised after
consulting the literature [4–13] and identifying factors that
could influence parental attitudes to involvement in clinical
research studies. Content and face validity were established byan expert panel of health care professionals including CF
clinical nurse specialists (CNS) and Consultant Paediatricians.
Revisions were based on their responses.
An identical, anonymised PAQwas administered to parents of
infants with CF and healthy controls when they attended their
first PFT at ~3 months of age. This consisted of one closed ended
question with six possible answers, parents being asked to
indicate reason(s) for involvement in the study by selecting all
that applied, together with an open ended question for additional
comments. A separate, anonymous questionnaire was adminis-
tered to parents of infants with CF by the CF CNS at first
clinic appointment following the ~12 month CT/BAL. The latter
consisted of both closed and open ended questions to elicit more
detailed responses. Data were collected between January 2009
and December 2011.2.2. Study subjects
Infants with CF diagnosed by NBS were recruited from the
London CF Collaboration (LCFC) comprising 6 specialist CF
centres [21–23]. Those born at N36 weeks gestation without
severe congenital, cardiovascular or neuromuscular disorders that
could impact on the respiratory system were eligible. Parents of
CF infants were approached at their first outpatient appointment
approximately 4 weeks following diagnosis (at approximately
6–8 weeks of age). A doctor or senior research nurse discussed
the study with the parents and gave a patient information sheet
(PIS) describing the study. Full consent for the study was sought
no less than one week later.
Healthy controls were identified using the birth register from
the Homerton University Hospital in East London, UK. Full-term
infants without congenital abnormalities, with birth weight
≥2500 g were eligible. General practitioners were contacted by
letter to ensure there were no medical and/or social contra-
indications for contacting potentially eligible families. Where
appropriate, parents were contacted by letter and then by tele-
phone to discuss if they would be interested in participating.
Ethical approval (# 09/HO71/314) was obtained from the
North Thames Multi-Centre Research Ethics Committee (REC)
and the local REC of the participating specialist centres.3. Results
3.1. Recruitment and retention
Fig. 1 shows recruitment and retention data. Between January
2009 and December 2011, 124 infants screened positive for CF.
Of those eligible, 92 (86%) agreed to participate; of whom 85
(92%) had PFTs at ~3 months of age. Of the 72 babies who had
reached ~12 months of age by December 2011, 71 (99%) had
PFTs and 65 (92%) had HRCT performed.
613 eligible healthy infants were identified, of whom 270
(44%) were contacted, with 77 (29%) of these families agreeing
to participate. Of these, 56 (73%) infants had PFTs at ~3 months
of age, of whom 83% (38/46) of those attaining their first birthday
by December 2011, had repeat PFTs.
Total PFT tested~ 1y: n=71 (99%). 
n=46 (82%) had reached their 1st
birthday at Dec 2011 
– 8 (17%) withdrawn from 1y PFT  
Total PFT tested~ 1y: n=38 (83%)
a) NBS infants with CF
n = 72 (86%) had reached 
their 1st birthday at Dec 2011  
-1 (1%) infant too old to be 
tested  
17 (14%) not 
eligible 
92 (86%) agreed to LF tests 
107 (86%) invited to participate 
124 screened positive
(14 [11%] had meconium ileus)
15 (14%) declined 
Total PFT tested 
~3m: n=85 (92%) 
Not tested: n=7 
(8%)     
 –5 (56%) withdrawn
–2 (25%) ‘too late’
193 (71%) declined 
613 eligible term infants identified 
Total PFT tested 
~3m: n=56 (73%) 
77 (29%) agreed to LF tests 
270 (44%): contacted 
Not tested: n=21 (27%)
(withdrawn or
‘ineligible’)
343 (56%): no response 
-6 (8%) withdrew from 
CT/BAL 
Total CT performed: n=65 (92%) 
b) Healthy controls
Fig. 1. Flow diagram showing the recruitment and retention of CF and HC infants in the study.
Table 1
Parental reasons for participating in a research study with their child at
3 months of age.
Reason Number of responses
CF Healthy
n 60 40
Help my child 59 (98%) 10 (25%)
Help other children with CF 58 (97%) 39 (98%)
Understood the study 44 (73%) 27 (68%)
No risk of harm 50 (83%) 32 (80%)
Plenty of time to consider what the study would involve 36 (60%) 15 (38%)
Didn't mind giving up time for the study 41 (68%) 27 (68%)
Results are presented as n (%).
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Completed questionnaires were available from 60/85 (71%)
parents of infants with CF at ~3 months and 41/71 (58%) at
~12 months of age. Questionnaires were completed by 40/56
(71%) parents of healthy infants at 3 months of age.
3.3. PAQs at 3 months of age
Table 1 summarises responses from parents regarding reasons
for participating in the study. All but two (3%) parents of infants
with CF indicated multiple reasons for participation. Additionally
at this stage 6/60 (10%) parents commented that they found the
process informative and reassuring and a further 6/60 (10%)
paid compliments to the staff involved. Similarly, all but one
(3%) parent of healthy infants indicated multiple reasons for
participating.3.4. PAQ at 1 year of age, infants with CF
Table 2 summarises responses from parents of infants with
CF after completion of all assessments at ~12 months when
Table 2
Parental reasons for having participated in a research study with their child with
CF at 1 year of age.
Reason Number of responses
(n=41)
Help my child 23 (56%)
Help other children with CF 20 (49%)
Assisting with research 13 (32%)
Finding a cure 5 (12%)
Increase parental knowledge 3 (7%)
Confident it was safe 2 (5%)
Results are presented as n (%).
Table 3
Reasons why parents of infants with CF would recommend involvement in a
research study to other parents.
Reason Number of responses
(n=41)
Help my child 16 (39%)
Help other children with CF 16 (39%)
Finding out more about CF 11 (27%)
Finding a cure 5 (12%)
Results are presented as n (%).
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All parents (n=41) felt that their children would receive the
same or better care as a result of participating in the research
and 93% believed future care would be better. Similarly, 88%
felt that having their child treated in a hospital that carried out
research was ‘good for their child’, whereas 12% felt it made no
difference.
When asked about how involvement in a research study
made them feel, 68% of parents stated they were happy and/or
not worried. A further 5% were happy but worried. Reasons for
this positivity included; feelings of helping their own child (29%)
and /or others with CF (27%), feeling their child was safe (20%)
and wanting to help with research (15%). One parent (2%) stated
s/he was unhappy since involvement made the diagnosis of CF a
‘reality’, while another had ‘no strong feelings’. Nine (22%)
parents were concerned about their child being involved in
research; reasons for this included ‘not knowing what to expect’
(12%), their child receiving a general anaesthetic (7%) and
‘concern over the findings’ (2%).
Sixteen parents (39%) felt that future children and/or
researchers would benefit from the study, while an additional
24 parents (59%) felt that their own child would benefit. One
parent felt that only the researchers would benefit from the
study. When asked about the advantages of participating, the
commonest reasons were ‘helping our own child’ (51%), ‘finding
out more about CF’ (27%) and ‘helping others with CF in the
future’ (24%).
When asked about potential negative aspects of participating
in research, the main issue appeared to be increased anxiety/
perceived risks or complications (15, 37%).While 95% of parents
would recommend being involved in research to other parents,
one parent was unsure and another chose not to answer. Of those
who would recommend participation to others, multiple reasons
were cited (see Table 3).
4. Discussion
4.1. Recruitment and retention
The findings from this study have shown that it is possible to
recruit infants diagnosed with CF by NBS within the first
three months postnatally to an observational study that requiressedation and/or general anaesthesia in order to obtain objec-
tive assessments of lung function and structure. They also
demonstrate the feasibility of sustained retention to such a study,
with N90% infants having PFTs at both 3 and 12 months of age.
These retention data are similar to those from a recent study of
NBS CF infants in Australia [24], which reported rates of clinic
attendance and attendance for annual CT and BAL of 90% and
85% respectively. However, this was a retrospective analysis and
no data were reported regarding recruitment rates. The recruit-
ment rates found in the current study for infants so soon after
initial diagnosis of CF by NBS, together with excellent retention
rates, have positive implications for future interventional studies.
This study also confirms that recruitment of contemporaneous
healthy control infants is feasible, albeit challenging, with only
29% of families contacted agreeing to participate in the study.
However, once recruited, retention of healthy infants was encour-
aging with repeat PFTs at 12 months of age being obtained
in78% of those tested at 3 months. Attrition at 1 year was
primarily due to work commitments or families moving home,
rather than dissatisfaction with the study.
4.2. PAQs at ~3 months of age
The response rate from the 3-month PAQs was good, both
for infants with CF and healthy controls (71%), with similar
reasons for participating being cited by both sets of parents.
Reasons for participation indicated by parents of children with
CF are consistent with those from a previous study involving
parents of preterm infants, which emphasised that having
adequate time to make decisions positively influenced decisions
to participate [8]. Similarly, in studies involving older children,
research involving low risk and perceived benefit had a positive
influence on parental agreement for their child's participation in
anaesthetic or surgical studies [10] as did provision of clear
parental information and adequate time to make decisions [11].
Unfortunately, ethical constraints prevented us from asking
parents who declined to be involved for reasons underlying this
decision.
Previous studies involving parents of healthy children empha-
sise that parental reasons for enrolling their child in research are
often altruistic and include benefitting other children in the future
[25], assisting with research [26] or both [27]. Other reasons
include; an opportunity to get their child checked regularly by
medical experts [25], the possibility of research benefitting their
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responsibility [27]. Such responses were also reflected in the
present study.
Although the present study did not request feedback from
those who declined, 68% of participating parents (both of healthy
infants and those with CF) stated they did not mind the extra time
required for the research, which is in contrast to previous reports
that this can act as a deterrent [13].
Despite all parents being informed in their respective PIS that
the study would not necessarily help their child per se, and that
any potential controls with known underlying respiratory con-
ditions had been excluded, 98% of parents of infants with CF and
25% of those with a healthy child felt that their child could benefit
by participating. Although, similar findings have been reported in
previous studies involving older children with asthma [25] and
vaccine studies [27], it is difficult to draw direct comparisons
with a NBS condition such as CF.
4.3. PAQ at 1 year of age, infants with CF
The 58% response rate for the PAQs administered at
~12 months of age was lower than that at 3 months, reflecting
the fact that, in contrast to the initial PAQ, administration of the
follow-up questionnaire occurred across multiple sites. Further-
more, in order to encourage frank responses, parents were
asked to return the anonymised PAQ to the co-ordinating centre
in a self-addressed envelope. This anonymity did however
preclude attempts to chase up non-responders, and alternative
approaches may be beneficial in future studies. This may limit
generalisability of results particularly to those families experienc-
ing organisational or social problems. Nevertheless, responses
that were obtained were generally positive, including the fact that
all parents felt their child and others in the future would receive
the same or better care as a result of participating. Similar reports
have been published when studying parents of preterm infants,
who believed it was good for their children to participate in
research and that this would lead to them receiving the same or
better care [4] or that it posed no harm and could benefit other
children in the future [9]. Although not relating to NBS issues,
these results are relevant to the present study, since both involve
recruitment of infants shortly after birth.
Despite clear statements in PIS that the study may not be of
any benefit to individual children, parental belief that this study
could help their own child was apparent on several occasions in
the ~12 month PAQ, thereby supporting results from the
~3 month PAQ. Parents of infants with CF also commented
that involvement in the present study could help find a cure for
CF, although there was no mention of this in the PIS. While this
could be attributed to misunderstanding regarding benefits of
research, as has been highlighted previously[26], it could also
reflect insight on the part of parents that carefully designed
research to evaluate the evolution of early changes in lung
function and structure, such in the current LCFC study, could
indeed pave the way for future trials of therapeutic interventions.
Although the majority of responses were very positive, parents
of infants with CF expressed some concerns regarding not
knowing what to expect (12%), their child receiving a generalanaesthetic (7%) and the implications of the findings (2%).
Additionally, when asked if there were any ‘bad’ things about
being involved parents expressed concerns over increased anxiety,
perceived risks or complications (37%). Other studies have
reported parental concerns about participating in research studies
[26], but state these are generally alleviated towards the end of the
study period. This finding is supported by results from this study in
that after completion of the 12-month investigations, many
indicated that they found the process informative and 39 (95%)
parents stated they would recommend being involved in research
study to other parents. Similar findings in a study investigating
children recruited to a randomised controlled trial, wherein 91% of
parents stated they would participate in a similar study in the future
[12], suggest that parents are generally not deterred by the research
process.
While 83% of parents indicated in the 3-month PAQ that one
of the reasons they chose to participate in the study was that they
felt there was ‘no risk of harm’, amongst those responding to the
12-month questionnaire only 5% were ‘confident it was safe’.
This apparent shift in parental views from the beginning to the
end of the study must be interpreted with caution, not least due to
the lower response rate at follow-up and the fact that the questions
were worded slightly differently on the two occasions. While this
could reflect limitations in the original PIS to explain all
procedures clearly enough, it may also reflect the fact that when
parents were invited to participate in the study, they may not have
been able to digest all of the information presented, both orally
and within the written PIS, due to the plethora of other details
imparted around the time of diagnosis. It was for this reason that
although the entire protocol was explained at the time of
recruitment, formal consent for the BAL and CT scans was not
sought until shortly before the 1 year tests, with parents being
given the option to ‘opt out’ of any particular aspect of the study.
Furthermore, the 12-month PAQ was completed shortly after
infants had been anaesthetised for their combined bronchoscopy
and CT. Parents were always present during induction of GA
which, despite its excellent safety record, understandably proved
to be an emotional experience for most parents of young infants.
Informal conversations with parents shortly after completion of
these procedures revealed not only the anxiety experienced at the
time of these invasive procedures and the relief once they were
completed, but invariably a positive attitude to having participat-
ed in the research study. The challenge of ensuring that parents
are not only fully informed but truly understand all aspects of a
proposed research study is one that is particularly pertinent when
recruiting infants to research studies at such a sensitive time and
will be an important consideration when designing future
intervention trials.
5. Conclusion
Recruitment shortly after diagnosis and subsequent retention
of infants diagnosed with CF by NBS to a study requiring
sedation or general anaesthesia in order to undertake serial
measures of lung function and structure in the first year of life is
feasible, as is recruitment of healthy control infants to a longi-
tudinal study of lung function. Parental attitudes to involvement in
239J. Chudleigh et al. / Journal of Cystic Fibrosis 12 (2013) 234–240such a study are positive. The results of this study provide
important evidence for the design of early therapeutic intervention
trials aimed at minimising or preventing lung disease in young
children with CF.Acknowledgements
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